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ETATE-OF-THE-ART PAPER705Genetic Predisposition to AFason D. Roberts, Michael H. Gollob
oberts and Gollob review studies that have begun to identify genes that may increase the
isk of lone atrial fibrillation (AF). A variety of ion channels have been implicated. The
ifferent causative genes may predispose to AF through a variety of mechanisms, including
ome that enhance and others that delay atrial action potential repolarization, while others
ffect cellular hyperexcitability and conduction velocity. The authors hope that someday
reatment for AF may be individualized based on the subclass of AF.YNCOPE713The ROSE Rule May Identify Patients With Syncope Who Require Admissionatthew J. Reed, David E. Newby, Andrew J. Coull, Robin J. Prescott, Keith G. Jacques, Alasdair J. Gray
eed and colleagues sought to develop and validate a clinical decision rule (CDR) to predict
-month serious outcome and all-cause death in patients presenting to an emergency
epartment with syncope. A CDR was devised from a derivation cohort and then tested in a
alidation cohort. Independent predictors of 1-month serious outcome were B-type natriuretic
eptide concentration 300 pg/ml, positive fecal occult blood, hemoglobin 90 g/l, oxygen
aturation 94%, and Q-wave on the electrocardiogram. The ROSE (Risk stratification Of
yncope in the Emergency department) rule, which recommends admission to the hospital if
ny of the above criteria are present, had a negative predictive value of 98.5% for serious
utcomes. The ROSE rule may be a valuable risk stratification tool for patients presenting
ith syncope.
ditorial Comment: David G. Benditt, Ilknur Can, p. 722(continued on page A-23)
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ETRIAL FIBRILLATION
725ATCH Score Predicts Which Patients Will Advance
From Paroxysmal to Sustained AFees B. de Vos, Ron Pisters, Robby Nieuwlaat, Martin H. Prins, Robert G. Tieleman,
obert-Jan S. Coelen, Antonius C. van den Heijkant, Maurits A. Allessie, Harry J. G. M. Crijns
e Vos and colleagues investigated which clinical factors would predict whether patients with
aroxysmal atrial fibrillation (AF) would develop a more sustained form of AF in the next
ear. Multivariate analysis showed that heart failure, age, previous transient ischemic attack
TIA) or stroke, chronic obstructive pulmonary disease, and hypertension were independent
redictors of AF progression. These risk factors were combined into the HATCH score, with
points for a history of heart failure and stroke or TIA. Nearly 50% of the patients with a
ATCH score 5 progressed to persistent AF versus 6% of the patients with a HATCH
core of 0.ditorial Comment: Arshad Jahangir, Shishir Murarka, p. 732TRIAL FIBRILLATION735The Risks/Benefits of Oral Anticoagulation After Successful AF Ablationakis Themistoclakis, Andrea Corrado, Francis E. Marchlinski, Pierre Jais, Erica Zado, Antonio Rossillo,
uigi Di Biase, Robert A. Schweikert, Walid I. Saliba, Rodney Horton, Prasant Mohanty, Dimpi Patel,
avid J. Burkhardt, Oussama M. Wazni, Aldo Bonso, David J. Callans, Michel Haissaguerre,
ntonio Raviele, Andrea Natale
ulmonary vein isolation is an effective treatment for atrial fibrillation (AF), but little is
nown about the subsequent risk of thromboembolism and thus the utility of continuing oral
nticoagulation (OAT). Themistoclakis and colleagues studied more than 3,000 patients, of
hom 80% discontinued OAT 3 to 6 months after ablation (Off-OAT group), while the
ther 20% remained on OAT (On-OAT group). During the 2-year follow-up, 0.07% of
ff-OAT group patients and 0.45% of On-OAT patients had an ischemic stroke. A major
emorrhage occurred in 1 Off-OAT patient and in 13 On-OAT patients. In this
onrandomized study, the risk–benefit ratio favors the suspension of OAT after successful
F ablation even in patients with a CHADS2 risk score of 2.
ditorial Comment: Ivan Cakulev, Albert L. Waldo, p. 744(continued on page A-24)
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ETRIAL FIBRILLATION747Chromosome 4q25 Variants Linked to AF Recurrence After Ablationaniela Husser, Volker Adams, Christopher Piorkowski, Gerhard Hindricks, Andreas Bollmann
ecent studies have identified 2 single nucleotide polymorphisms on chromosome 4q25 as
ossibly related to atrial fibrillation (AF). This chromosomal location is in a noncoding region
ut is close to the gene PITX2, which is important for myocardium development in the
ulmonary veins. Husser and colleagues genotyped almost 200 subjects who underwent AF
atheter ablation and then performed serial 7-day Holter electrocardiogram recordings to
etect AF recurrences. The presence of either variant allele doubled the risk for early AF
ecurrence (within the first 7 days) and more than quadrupled the risk for late AF recurrence
within 6 months). Polymorphisms on chromosome 4q25 modulate the risk for AF
ecurrence after catheter ablation.ditorial Comment: Jennifer L. Hall, Ana Barac, Emelia J. Benjamin, p. 754TRIAL FIBRILLATION758Aldosterone May Underlie Atrial Ionic Remodeling During AFhia-Ti Tsai, Fu-Tien Chiang, Chuen-Den Tseng, Juey-Jen Hwang, Kuan-Ting Kuo, Cho-Kai Wu,
hih-Chieh Yu, Yi-Chih Wang, Ling-Ping Lai, Jiunn-Lee Lin
sai and colleagues studied the role of steroidogenesis proteins and aldosterone in the atrium,
nd their possible role in triggering or maintaining atrial fibrillation (AF). Patients with AF
ad significantly higher atrial mineralocorticoid receptor (MR) expression compared with
hose with normal sinus rhythm. Rapid depolarization, mimicking AF, increased MR
xpression in a cellular model through a calcium-dependent mechanism. Aldosterone
ncreased oxidative stress in these cells and increased the number of T-type calcium channels,
hich led to increased intracellular calcium load. These results help to identify the role of
ldosterone and MR in the atrial remodeling that occurs during AF.
ditorial Comment: Panagiotis Korantzopoulos, John A. Goudevenos, p. 771(continued on page A-28)
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EMPLANTABLE CARDIOVERTER-DEFIBRILLATORS774Frequency of Complications After Defibrillator Implantation0%
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r        Chamberouglas S. Lee, Andrew D. Krahn, Jeffrey S. Healey, David Birnie, Eugene Crystal, Paul Dorian,
hristopher S. Simpson, Yaariv Khaykin, Douglas Cameron, Amir Janmohamed, Raymond Yee,
eter C. Austin, Zhongliang Chen, Judy Hardy, Jack V. Tu, for the Investigators of the
ntario ICD Database
ee and colleagues used a mandated registry of all newly-implanted cardioverter-defibrillators
ICDs) at 18 centers to determine the rate of early complications after these procedures.
ajor complications occurred in 4.1% of de novo procedures. Compared with those
mplanted with a single-chamber device, implantation of a cardiac resynchronization therapy
efibrillator (CRT-D) (adjusted hazard ratio [HR]: 2.2) or dual-chamber device (HR: 1.8)
ncreased the risk of major complications. Major complications were those that required a
ubsequent procedure, hospitalization, substantive parenteral therapy, or death. Complications
fter ICD implantation are strongly associated with device type; these complications also
ncrease the risk of death.ONG QT SYNDROME
783atients With LQTS Who Experience Syncope While
Taking Beta-Blockers Are at High Risk for Subsequent Eventshristian Jons, Arthur J. Moss, Ilan Goldenberg, Judy Liu, Scott McNitt, Wojciech Zareba, Ming Qi,
ennifer L. Robinson
hile syncope is known to predict future fatal arrhythmias in patients with long QT
yndrome (LQTS), there is no data regarding risk stratification for LQTS patients who
nitially present with syncope. More than 1,000 patients presenting with syncope as a first
ymptom were drawn from the International LQTS Registry. The main end point was a
evere arrhythmic event (SAE) comprising aborted cardiac arrest, appropriate implantable
ardioverter-defibrillator therapy, and sudden cardiac death. The lowest risk for SAEs was in
atients with only 1 syncopal episode before starting beta-blocker therapy. Patients
xperiencing syncope while on beta-blockers had a 3.6-fold increased risk for SAEs relative to
he low-risk group. LQTS patients with syncope during beta-blocker therapy are at high risk
or life-threatening events, and ICD therapy should be considered.RUGADA SYNDROME789ECG Abnormalities Seen in Brugada Syndrome Localize to the Right VentricleV I
LR
DRL F
Additional Frank leads
Body surface map leads
Leads selected for right and left precordial set
I E M
H
ieter G. Postema, Pascal F. H. M. van Dessel, Jan A. Kors, Andre C. Linnenbank, Gerard van Herpen,
enk J. Ritsema van Eck, Nan van Geloven, Jacques M. T. de Bakker, Arthur A. M. Wilde, Hanno L. Tan
ostema and colleagues studied changes in various electrocardiographic depolarization and/or
epolarization variables that produce the type 1 Brugada Syndrome (BrS) electrocardiogram
ECG) during ajmaline provocation testing. Simultaneous recordings of ECG,
ectorcardiogram, and body surface potential maps were obtained. The type 1 ECG was
aused by right terminal conduction delay in combination with an increase in late potentials
n the right precordial leads, but not with repolarization abnormalities. The type 1 BrS ECG
s caused predominantly by localized depolarization abnormalities in the right ventricle.ditorial Comment: Martin Borggrefe, Rainer Schimpf, p. 798
(continued on page A-31)
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aORSADE DE POINTES801Ranolazine Reduces Torsades de Pointes in a Dog Modeludrun Antoons, Avram Oros, Jet D. M. Beekman, Markus A. Engelen, Marien J. C. Houtman,
uiz Belardinelli, Milan Stengl, Marc A. Vos
ntoons and colleagues investigated whether ranolazine reduces dofetilide-induced torsades
e pointes (TdP) in a model of long QT syndrome: the dog with chronic atrioventricular
lock (cAVB). Ranolazine reduced the number of TdP episodes and partially reversed the
ncrease of beat-to-beat variability of repolarization without affecting the dofetilide-induced
T prolongation. In cAVB myocytes, ranolazine suppressed dofetilide-induced early after
epolarizations. The antiarrhythmic activity of ranolazine in cAVB dogs appears to be
hrough reduced late Na current; these results help us to understand the antiarrhythmic
ffects of ranolazine.INTERVENTIONAL CARDIOLOGY NTERVENTIONAL CARDIOLOGY810SES Safely Reduces the Rate of TLR Post-STEMI Compared With BMSoberto Violini, Carmine Musto, Francesco De Felice, Marco Stefano Nazzaro, Alberta Cifarelli,
ommasangelo Petitti, Rosario Fiorilli
he SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal Stent In Acute Myocardial
nfarction) trial randomized 320 ST-segment elevation myocardial infarction (STEMI)
atients to either a sirolimus-eluting stent (SES) or a bare-metal stent (BMS). Previously
eported 1-year outcomes showed reduced rates of target lesion revascularization (TLR) with
ES. This report by Violini and colleagues extends the follow-up period to 3 years, which is
mportant given the concern for possibly higher rates of stent thrombosis (ST) with SES after
topping clopidogrel. The 3-year incidence of major adverse cardiovascular events (MACE)
as lower in the SES group compared with the BMS group (12.5% vs. 21%), driven
rimarily by reduced TLR. The cumulative incidence of death and re-myocardial infarction,
tarting from clopidogrel discontinuation, was comparable in the 2 groups, with no evidence
f higher rates of ST with SES. The clinical benefits of SES over BMS for STEMI patients
re maintained at 3 years in this randomized trial.(continued on page A-32)
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aNTIPLATELET THERAPY815Slow Response Predicts Low Response for Clopidogrelnne Bellemain-Appaix, Gilles Montalescot, Johanne Silvain, Olivier Barthélémy, Farzin Beygui,
ean-Philippe Collet, Georges Sideris, Catherine Meuleman, Claire Bal-dit-Sollier, Nicolas Lellouche,
régory Ducrocq, Michel Slama, Olivier Milleron, Patrick Henry, Ludovic Drouet, for the
LBION Investigators
his post-hoc analysis of the ALBION (Assessment of the Best Loading Dose of
lopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) study assessed
arly kinetic profiles of adenosine diphosphate-induced maximal platelet aggregation (MPA)
nd MPA, with measurements at 8 time points during the 24 h after clopidogrel loading
300, 600, or 900 mg). Low response was defined as MPA 10% and fast response as
MPA 10% within the first hour after loading. Fifty-five percent of subjects were slow
esponders, and these subjects were twice as likely to have high post-treatment platelet
eactivity. The response to clopidogrel within the first hour of administration is a reliable
arker of the final clopidogrel response.HYPERTROPHIC CARDIOMYOPATHY YPERTROPHIC CARDIOMYOPATHY823Meta-Analysis of Septal Alcohol Ablation Compared With Septal Myectomyhikhar Agarwal, E. Murat Tuzcu, Milind Y. Desai, Nicholas Smedira, Harry M. Lever, Bruce Lytle,
amir R. Kapadia
garwal and colleagues performed a systematic review and meta-analysis of 12 studies
omparing outcomes of septal ablation (SA) and septal myectomy (SM) for the treatment of
ypertrophic obstructive cardiomyopathy (HOCM). No significant differences between short-
nd long-term mortality were found. In addition, no significant differences were found in
ost-intervention functional status, ventricular arrhythmia occurrence, reinterventions
erformed, and post-procedure mitral regurgitation. However, SA was associated with a
.6-times higher risk for permanent pacemaker implantation. Both SA and SM are effective
reatments for HOCM; the preferred procedure for an individual patient will depend on
vailable resources and informed decision making.
